Reports out of the gene therapy ecosystem highlight complications around viral delivery risk and the trade-offs between immunosuppression and efficacy. One story describes how steroids commonly used to blunt immune responses in an AAV-based Dravet syndrome trial were also associated with concerns about reduced gene-therapy effectiveness, with sirolimus added for some patients. Separately, another report links a rare brain tumor case in a young patient to investigation into whether vectors used in a gene therapy may have contributed—underscoring how rare adverse events can reshape scientific and regulatory discussions. Together, the coverage reinforces that next-generation gene therapy programs increasingly rely not only on potency data but also on manageability of immune and safety outcomes during and after dosing.